Bausch Health Companies Inc. diskutieren
Bausch Health Companies Inc.
WKN: A2JQ1X / Symbol: BHC / Name: Bausch Health Companies / Aktie / Pharmazeutika / Mid Cap /
ftrader stimmt dem Sentiment von 'Buy' zu
ftrader stimmt am 09.02.2016 dem Buy-Gesamtsentiment mit dem Kursziel 159.09€ zu.
Valeant kommt wieder auf die Beine
Hallo Ihr Shareweisen
Habe gerade 2 Kilo Valeant gekauft.
Hier ist ein schnelles Erholungspotenzial.
Eine Zahlungsunfähigkeit wird es kurzfristig nicht geben.
Eher sehe ich hier ein längerfristiges Pendeln der Aktie.
Also immer gut absichern.
Auch bei Ausbrüchen nach oben immer ein Teil der Aktien verkaufen.
Bei starken Gegenbewegungen wieder zukaufen.
Ein Abenteuer ist es allemal, aber eine Möglichkeit sein Depotwert zu steigern.
LG Waltaurus
haussier
pharma
neue Besen kehren gut
nach wie vor aber mit großem Risiko behaftet!
Valeant Pharma Initiates Search For New CEO; Plans Restatement - Quick Facts
(RTTNews.com) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced its board has initiated a search to identify a candidate to succeed Michael Pearson as CEO. The company also announced William Ackman, CEO of Pershing Square Capital Management, L.P., will join its board, effective immediately. Katharine Stevenson voluntarily resigned from the Board to create a vacancy for Ackman's appointment.
Valeant Pharma said it has identified misstatements that would reduce previously reported fiscal year 2014 revenue by approximately $58 million, net income attributable to Valeant by approximately $33 million, and earnings per share by $0.09. The company has identified misstatements in the first quarter of 2015, consisting primarily of the reversing effect on earnings of the 2014 misstatements, which would reduce revenue by approximately $21 million, increase net income attributable to Valeant by approximately $24 million and increase earnings per share by $0.07.
The company said it is in the process of restating the affected financial statements and the restated financial statements will be included in the company's Annual Report on Form 10-K for the year ended December 31, 2015, which the company intends to file with the SEC and the Canadian Securities Regulators on or before April 29, 2016.
kyron7htx stimmt dem Sentiment von 'Buy' zu
kyron7htx stimmt am 13.05.2016 dem Buy-Gesamtsentiment mit dem Kursziel 106.58$ zu.
ich wage es nochmal
nach wie vor aber mit großem Risiko behaftet!
Valeant Pharma Initiates Search For New CEO; Plans Restatement - Quick Facts
(RTTNews.com) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced its board has initiated a search to identify a candidate to succeed Michael Pearson as CEO. The company also announced William Ackman, CEO of Pershing Square Capital Management, L.P., will join its board, effective immediately. Katharine Stevenson voluntarily resigned from the Board to create a vacancy for Ackman's appointment.
Valeant Pharma said it has identified misstatements that would reduce previously reported fiscal year 2014 revenue by approximately $58 million, net income attributable to Valeant by approximately $33 million, and earnings per share by $0.09. The company has identified misstatements in the first quarter of 2015, consisting primarily of the reversing effect on earnings of the 2014 misstatements, which would reduce revenue by approximately $21 million, increase net income attributable to Valeant by approximately $24 million and increase earnings per share by $0.07.
The company said it is in the process of restating the affected financial statements and the restated financial statements will be included in the company's Annual Report on Form 10-K for the year ended December 31, 2015, which the company intends to file with the SEC and the Canadian Securities Regulators on or before April 29, 2016.
piccolo90 stimmt dem Crowdsentiment von 'Buy' zu
piccolo90 stimmt am 09.08.2016 dem Buy-Crowdsentiment mit dem Kursziel 49.41C$ zu.
woelli stimmt dem Crowdsentiment von 'Buy' zu
woelli stimmt am 24.08.2016 dem Buy-Crowdsentiment mit dem Kursziel 48.73$ zu.
Valeant Pharma: auf lange Sicht ein Investment Wert
auf lange Sicht sind auch 45$ als Ziel erreichbar.
(Das Allzeit hoch lag bei 260$.)
woelli stimmt dem Crowdsentiment von 'Buy' zu
woelli stimmt am 01.11.2016 dem Buy-Crowdsentiment mit dem Kursziel 42.5$ zu.
VRX
The Canadian firm now expects adjusted earnings of $5.30 to $5.50 a share on $9.55 billion to $9.65 billion in sales for the year. That is down sharply from its previous guidance for earnings of $6.60 to $7 a share and revenue between $9.9 billion and $10.1 billion.
Stier
Die Aktien von Valeant Pharmaceuticals International, Inc. (NYSE: VRX) handeln im positiven Bereich Freitag, nach einem Bericht sagte , dass Intereconomia der größte Pharmakonzern in Asien Takeda Pharmaceutical Co. Ltd. (OTCMKTS: TKPYY) erhielt $ 13 Milliarden von HSBC und Deutsche Bank Übernahmeverhandlungen mit Valeant fortzusetzen.
Neueste Beiträge
Subdi in Tesla Inc diskutieren